About the Company
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Employees
27
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SESN News
SESEN BIO, INC. (SESN) Gains As Market Dips: What You Should Know
SESEN BIO, INC. (SESN) closed the most recent trading day at $0.56, moving +1.8% from the previous trading session. The stock outpaced the S&P 500's daily loss of 1.06%. Meanwhile, the Dow lost 0. ...
Carisma Therapeutics (CARM) Price Target Decreased by 10.00% to 9.18
The average one-year price target for Carisma Therapeutics (NasdaqGM:CARM) has been revised to 9.18 / share. This is an ...
Sesen Bio Stock Drops After FDA Decision, Wainwright Cut to Neutral
The shares are lower. Sesen Bio (SESN) shares dropped on Monday, extending Friday’s decline, as HC Wainwright downgraded the drugmaker after the FDA last week denied marketing clearance for ...
Carisma Therapeutics (CARM) Price Target Increased by 8.33% to 9.95
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as ...
Buy Rating on Carisma Therapeutics: Pioneering CAR-M Therapies in Oncology and Fibrosis
Analyst Naureen Quibria of Capital One Financial reiterated a Buy rating on Carisma Therapeutics (CARM – Research Report), retaining the ...
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carisma”) management team on ...
Carisma lets go of 37% of staff, CAR-M candidate to stretch cash runway
Since increasing its head count via a reverse merger with Sesen Bio in March 2023, Carisma's personnel costs have climbed. Now, the biotech is trimming the team and implementing a revised ...
Buy Rating Affirmed on Carisma Therapeutics Amid Promising Early Research and Pipeline Potential
Carisma Therapeutics (CARM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
2seventy bio, Inc. (TSVT)
April 01, 2024--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement ("APA") by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron ...
CARM Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States.
bluebird bio, Inc. (BLUE)
SOMERVILLE, Mass., April 11, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 ...
THRD Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops inflammatory diseases ...
Loading the latest forecasts...